Evaluating higher doses of Ivermectin for COVID-19 treatment
Official title: Clinical Study Evaluating the Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment
Run by Tanta University · NCT04351347 · Data updated 2026-11-12
This study is testing whether higher doses of Ivermectin can help people with COVID-19 feel better and recover faster.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Tanta) |
| Status | Recruiting |
| Started | June 16, 2020 |
| Main results expected | December 1, 2030 |
| Study ends | December 1, 2030 |
| Registry record updated | March 10, 2021 |
| Trial ID | NCT04351347 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients who have been diagnosed with COVID-19.
✕Probably not a fit
Patients who have allergies or adverse reactions to Ivermectin will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the efficacy of administering larger doses of Ivermectin to patients diagnosed with COVID-19. The study is designed as an interventional trial, encompassing both Phase 2 and Phase 3 evaluations to assess the treatment's effectiveness and safety. Participants will receive Ivermectin, and their health outcomes will be monitored to determine any improvements in COVID-19 symptoms and recovery rates.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for patients suffering from COVID-19.
How similar studies have gone: While some studies have explored the use of Ivermectin for COVID-19, the efficacy of higher doses remains a relatively novel approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with covid 19 Exclusion Criteria: * Allergy or side effects to treatment
Where it's running
-
Tanta University
Tanta, Egypt Recruiting
Study contacts
- Principal investigator: sherief Abd-Elsalam, Ass. Prof. — Tanta University - Faculty of Medicine
- Study coordinator: Sherief Abd-Elsalam, ass. prof.
- Email: sheriefabdelsalam@yahoo.com
- Phone: 00201147773440
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Effects of suctioning on pain and stress in intubated ICU patients
This study is testing if suctioning the breathing tube in ICU patients causes more pain and stress compared to not suctioning.
-
Survey on COVID-19 impact in patients with primary immune deficiency
This study is trying to learn how COVID-19 has affected people with primary immune deficiencies to better understand their experiences and outcomes.
-
New treatments for COVID-19 using nitazoxanide and ivermectin
This study is testing if the medications nitazoxanide and ivermectin, alone or with other drugs, can help people with COVID-19 feel better.
-
Understanding the long-term effects of COVID-19 infection
This study looks at people who have recovered from COVID-19 to see how the infection affects their health over time.
-
Chilblain-like skin changes during COVID-19 infection
This observational study looks at people with COVID-19 who develop skin lesions that look like chilblains to see what these sores have in common and what they might mean for the disease overall.
-
Investigating COVID-19 in hospitalized children in Norway
This study looks at how COVID-19 affects children in hospitals in Norway to see what makes some kids sicker than others and to understand the long-term effects of the virus.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.